
Incyte (INCY) Stock Forecast & Price Target
Incyte (INCY) Analyst Ratings
Bulls say
Incyte is a biotech company with strong potential for long-term growth, highlighted by their diversified portfolio which is expected to drive an increase in revenue from $1.7B in 2026 to $3-4B in 2030. The recent acquisition of Vega Therapeutics adds the potential blockbuster drug VGA039, which could become the new standard of care for VWD patients, and has a conservative peak sales estimate of $1B+. With a strong pipeline and strategic acquisitions, Incyte is well-positioned for success in the biotech industry, although risks include slower market uptake and delays in securing approvals for late-stage candidates.
Bears say
Incyte is currently overvalued with its DCF-based valuation showing an enterprise value of ~$28B, while the company's current market cap is over $33B. Risks include slower-than-expected market uptake for its drugs, delays in securing approvals for late-stage candidates, and failure to generate favorable data from ongoing programs. The recent deal expansion with Genesis adds significant capital commitment and data integration, while also increasing the target count and potential milestones. Jakafi, the company's leading drug, has shown steady sales growth but may face competition in the future.
This aggregate rating is based on analysts' research of Incyte and is not a guaranteed prediction by Public.com or investment advice.
Incyte (INCY) Analyst Forecast & Price Prediction
Start investing in Incyte (INCY)
Order type
Buy in
Order amount
Est. shares
0 shares